Download App

Log in to access Online Inquiry
Company Overview More
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual’s tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
CEO: --
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

NTRA Natera
38.970+3.040+8.46%
Pre Mkt Price
38.97000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
15.05% 751.96M 24.01% 914.28M 24.01% 914.28M 26.45% 1.02B
-Cash and cash equivalents
143.06% 158.3M 73.39% 84.39M 73.39% 84.39M -54.57% 95.1M
-Short-term investments
0.89% 593.66M 20.52% 829.9M 20.52% 829.9M 54.71% 928.6M
Receivables
91.71% 167.86M 55.38% 122.07M 55.38% 122.07M 56.23% 110.42M
-Accounts receivable
91.71% 167.86M 55.38% 122.07M 55.38% 122.07M 56.23% 110.42M
Inventory
5.79% 25.05M 34.34% 26.91M 34.34% 26.91M 37.52% 28.02M
Prepaid assets
32.92% 35.13M 11.42% 29.65M 11.42% 29.65M 89.52% 28.86M
Restricted cash
39.88% 228K 21.93% 228K 21.93% 228K 28.09% 228K
Total current assets
23.86% 980.23M 26.72% 1.09B 26.72% 1.09B 30.04% 1.19B
Non current assets
Net PPE
59.15% 142.76M 127.46% 124.53M 127.46% 124.53M 120.31% 106.95M
-Gross PPE
16.07% 165.18M 37.35% 143.94M 37.35% 143.94M 71.77% 165.26M
-Accumulated depreciation
57.39% -22.42M 61.22% -19.41M 61.22% -19.41M -22.34% -58.31M
Other non current assets
74.72% 21.68M 27.65% 18.82M 27.65% 18.82M 8.6% 13.2M
Total non current assets
61.04% 164.44M 106.29% 143.35M 106.29% 143.35M 97.94% 120.15M
Total assets
28.11% 1.14B 32.65% 1.24B 32.65% 1.24B 34.26% 1.31B
Liabilities
Current liabilities
Payables
223.3% 18.86M 199.79% 29.44M 199.79% 29.44M -6.72% 9.94M
-accounts payable
285.95% 18.07M 236.04% 27.21M 236.04% 27.21M -11.56% 8.18M
-Total tax payable
-31.54% 788K 29.43% 2.23M 29.43% 2.23M 25.12% 1.76M
Current accrued expenses
87.35% 93.28M 100.37% 68.16M 100.37% 68.16M 72.13% 71.93M
Current provisions
-14.67% 17.33M -0.9% 17.21M -0.9% 17.21M 19.19% 15.88M
Current debt and capital lease obligation
-1.44% 55.29M -2.7% 55.8M -2.7% 55.8M 0.96% 56.97M
-Current debt
0.01% 50.06M -0% 50.05M -0% 50.05M -0.01% 50.05M
-Current capital lease obligation
-13.39% 5.24M -21.21% 5.75M -21.21% 5.75M 8.5% 6.92M
Current deferred liabilities
53.42% 13.91M -85.23% 7.4M -85.23% 7.4M -81.13% 9.67M
Current liabilities
38.39% 231.07M 10% 218.96M 10% 218.96M 1.96% 199.71M
Non current liabilities
Long term debt and capital lease obligation
5.42% 348.18M 52.6% 341.43M 52.6% 341.43M 48.36% 328.47M
-Long term debt
0.44% 280.71M 38.47% 280.39M 38.47% 280.39M 40.07% 280.09M
-Long term capital lease obligation
32.8% 67.48M 187.28% 61.04M 187.28% 61.04M 125.65% 48.39M
Non current deferred liabilities
-13.74% 20.54M -6.52% 21.32M -6.52% 21.32M -1.82% 22.71M
Other non current liabilities
-- 2.53M 362.19% 1.48M 362.19% 1.48M 372.26% 1.46M
Total non current liabilities
4.85% 371.26M 47.54% 364.23M 47.54% 364.23M 44.03% 352.64M
Total liabilities
15.6% 602.33M 30.78% 583.18M 30.78% 583.18M 25.33% 552.36M
Shareholders'equity
Share capital
11.11% 10K 11.11% 10K 11.11% 10K 11.11% 10K
-common stock
11.11% 10K 11.11% 10K 11.11% 10K 11.11% 10K
Retained earnings
-55.37% -1.53B -50.09% -1.39B -50.09% -1.39B -47.06% -1.25B
Paid-in capital
54.08% 2.09B 45.29% 2.05B 45.29% 2.05B 45.39% 2.01B
Gains losses not affecting retained earnings
-534.91% -13.9M -153.7% -2.29M -153.7% -2.29M -71.16% 1.49M
Total stockholders'equity
45.61% 542.34M 34.36% 653.3M 34.36% 653.3M 41.61% 759.02M
Total equity
45.61% 542.34M 34.36% 653.3M 34.36% 653.3M 41.61% 759.02M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion with Explanation----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%